title: Do cells need CDK2 and ... Bcr-Abl?
authors.affiliation: Brander Cancer Research Institute, New York Medical College, Valhalla, NY 10532, USA. M_Blagosklonny@nymc.edu
authors.forename: M V
authors.initials: MV
authors.lastname: Blagosklonny
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D042846:CDC2-CDC28 Kinases / Q000378:metabolism*; D051357:Cyclin-Dependent Kinase 2; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D018922:HL-60 Cells; D006801:Humans; D000068877:Imatinib Mesylate; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy; D008954:Models, Biological; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D042846:CDC2-CDC28 Kinases; C495894:CDK2 protein, human; D051357:Cyclin-Dependent Kinase 2